Anti-SHISA8 monoclonal antibody

Pre-made anti-SHISA8 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to SHISA8/SHISA8 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1638-Ab-1/ GM-Tg-hg-IP1638-Ab-2Anti-Human SHISA8 monoclonal antibodyHuman
GM-Tg-rg-IP1638-Ab-1/ GM-Tg-rg-IP1638-Ab-2Anti-Rat SHISA8 monoclonal antibodyRat
GM-Tg-mg-IP1638-Ab-1/ GM-Tg-mg-IP1638-Ab-2Anti-Mouse SHISA8 monoclonal antibodyMouse
GM-Tg-cynog-IP1638-Ab-1/ GM-Tg-cynog-IP1638-Ab-2Anti-Cynomolgus/ Rhesus macaque SHISA8 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1638-Ab-1/ GM-Tg-felg-IP1638-Ab-2Anti-Feline SHISA8 monoclonal antibodyFeline
GM-Tg-cang-IP1638-Ab-1/ GM-Tg-cang-IP1638-Ab-2Anti-Canine SHISA8 monoclonal antibodyCanine
GM-Tg-bovg-IP1638-Ab-1/ GM-Tg-bovg-IP1638-Ab-2Anti-Bovine SHISA8 monoclonal antibodyBovine
GM-Tg-equg-IP1638-Ab-1/ GM-Tg-equg-IP1638-Ab-2Anti-Equine SHISA8 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1638-Ab-1/ GM-Tg-hg-IP1638-Ab-2; GM-Tg-rg-IP1638-Ab-1/ GM-Tg-rg-IP1638-Ab-2;
GM-Tg-mg-IP1638-Ab-1/ GM-Tg-mg-IP1638-Ab-2; GM-Tg-cynog-IP1638-Ab-1/ GM-Tg-cynog-IP1638-Ab-2;
GM-Tg-felg-IP1638-Ab-1/ GM-Tg-felg-IP1638-Ab-2; GM-Tg-cang-IP1638-Ab-1/ GM-Tg-cang-IP1638-Ab-2;
GM-Tg-bovg-IP1638-Ab-1/ GM-Tg-bovg-IP1638-Ab-2; GM-Tg-equg-IP1638-Ab-1/ GM-Tg-equg-IP1638-Ab-2
Products NameAnti-SHISA8 monoclonal antibody
Formatmab
Target NameSHISA8
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-SHISA8 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1638-Ag-1Recombinant multi-species SHSA8/ SHISA8/ C22orf17 protein


    Target information

    Target IDGM-IP1638
    Target NameSHISA8
    Gene ID440829,435145,315163,100424549,609682,101090120,618510,100070715
    Gene Symbol and SynonymsC22orf17,ckamp39,Orf26,RGD1563996,SHISA8
    Uniprot AccessionB8ZZ34
    Uniprot Entry NameSHSA8_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000234965
    Target ClassificationN/A

    The target: SHISA8, gene name: SHISA8, also named as C22orf17, Orf26. Predicted to be involved in regulation of AMPA receptor activity and regulation of short-term neuronal synaptic plasticity. Predicted to be integral component of membrane. Predicted to be part of AMPA glutamate receptor complex. Predicted to be active in dendritic spine membrane; postsynaptic density; and postsynaptic membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.